Anadrol vs Telmisartan
FDA Approved vs FDA Approved
avoid Mechanism-based · 75% Both Anadrol and Telmisartan carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
Anadrol Telmisartan
Weight 332.48 Da 514.62 Da
Half-life ~8-9 hours ~24 hours
Type 17-alpha alkylated anabolic steroid (C21H32O3) Benzimidazole derivative (C33H30N4O2)
Key Benefits
Anadrol
01 Rapid and dramatic increases in muscle mass and bodyweight
02 Exceptional strength gains, often noticeable within the first week
03 Potent stimulation of erythropoietin and red blood cell production
04 Increased appetite and nutrient partitioning in some users
05 Improved recovery between training sessions
06 Full, round muscle appearance due to intramuscular water and glycogen retention
07 FDA-approved treatment for various forms of anemia
Telmisartan
01 Potent 24-hour blood pressure reduction with once-daily dosing
02 Protection against AAS-induced left ventricular hypertrophy and cardiac remodeling
03 Nephroprotection through reduced intraglomerular pressure and proteinuria
04 Unique partial PPAR-gamma agonism improving insulin sensitivity and lipid metabolism
05 No negative impact on exercise performance, VO2 max, or recovery
06 Reduction of pathological vascular remodeling and arterial stiffness
07 Longest half-life of all ARBs ensuring consistent 24-hour coverage
08 Well-tolerated with a low incidence of side effects compared to ACE inhibitors (no dry cough)
Side Effects
Anadrol
Significant water retention and bloating (estrogenic, not aromatase-mediated)
Elevated blood pressure (fluid volume and RBC increase)
Severe liver stress and elevated liver enzymes (AST/ALT)
Back pumps and lower back pain during exercise
Headaches (often blood pressure-related)
Appetite suppression (paradoxical for a mass-building compound)
Lethargy and fatigue (hepatic strain-related)
Acne and oily skin
Suppression of natural testosterone production
Telmisartan
Dizziness or lightheadedness, particularly during the first few days or after dose increases
Mild hypotension, especially in volume-depleted individuals or those on concurrent antihypertensives
Upper respiratory tract infection symptoms (sinusitis, pharyngitis) - reported in clinical trials at rates similar to placebo
Back pain and myalgia (uncommon but reported)
Fatigue
Contraindications
Pre-existing liver disease or significantly elevated liver enzymes
Prostate cancer or breast cancer in males
Nephrotic phase of nephritis
Hypercalcemia (Anadrol can exacerbate calcium levels)
Pregnancy (Category X - causes virilization of the female fetus)
Known hypersensitivity to oxymetholone
Concurrent use of other 17-alpha alkylated oral steroids (compounded liver toxicity)
Pregnancy (Category D - can cause fetal injury and death; discontinue immediately if pregnancy is detected)
Bilateral renal artery stenosis
Known hypersensitivity to telmisartan or any excipients
Concurrent use with aliskiren in patients with diabetes or renal impairment (eGFR <60)
Severe hepatic impairment or biliary obstruction (telmisartan is eliminated primarily via biliary excretion)
Research Evidence
Anadrol Telmisartan
Status FDA Approved FDA Approved
References 5 studies 5 studies
Latest 2018 2023
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.